Navin Fluorine Q1FY27 earnings surge as CDMO and Advanced Materials expand

Investment View and Key Takeaways

ICICI Securities maintained its BUY recommendation on Navin Fluorine International following a strong Q1FY27 performance and continued progress across its High Performance Products, Speciality Chemicals and CDMO businesses. The investment case is supported by sustained segment momentum, planned capacity additions, the development of an Advanced Materials vertical and execution in the CDMO portfolio.

The broker values Navin Fluorine at 45x FY28E EPS and derives a target price of Rs 9,635, stating that the company’s growth momentum and execution warrant a premium valuation.

Strong Q1FY27 Financial Performance

Navin Fluorine reported Q1FY27 revenue of Rs 1,045 crore, representing 44 per cent year-on-year growth. EBITDA increased 73 per cent year-on-year to Rs 357 crore, while EBITDA margin expanded by around 566 basis points year-on-year to 34.2 per cent. PAT increased 108 per cent year-on-year to Rs 243 crore.

Gross profit margin was 57 per cent, down around 60 basis points year-on-year. Segment-wise performance was as follows:

CDMO Expansion and Pipeline Progress

Management reiterated its target of approximately US$100 million of CDMO revenue in FY27. The CDMO pipeline comprises around 30 to 40 active molecules, including approximately 10 in late-stage development. Three to four molecules are expected to receive regulatory or FDA readouts over the next 8 to 12 months.

The Board approved Rs 125 crore for Phase II expansion of the cGMP4 facility, supported by increasing demand from an existing European customer. The company will also participate at the API-1 level for an additional molecule in the same supply chain.

The earlier Rs 288 crore cGMP expansion remains on track. Phase I was commissioned in Q3FY26, while Phase II is expected to become operational by Q4FY27. Management expects approximately 3x asset turnover from this investment by around FY29, with potential further upside.

Advanced Materials: New Strategic Growth Vertical

Navin Fluorine is developing Advanced Materials as a separate strategic business focused on semiconductors, electronics, data centres and defence. The company has approved Rs 90 crore of internally funded capex for adoption-scale manufacturing. This investment is intended to support commercial-scale customer qualification after laboratory-scale qualification.

Around four to five products have received initial customer approval, while another four to five products are entering the development pipeline. Management ultimately envisages Advanced Materials becoming comparable in scale and strategic importance to the current CDMO business.

The company has also partnered with DRDO to develop domestic Sodium Borohydride production and expects to be the sole domestic producer.

High Performance Products and Speciality Chemicals Outlook

High Performance Products

An additional 15,000 MTPA of R32 capacity, compared with current capacity of 9,000 tonnes, remains scheduled for commissioning in Q3FY27. Management plans to place around 35 to 45 per cent of R32 capacity under five-year contracts, retaining the balance for spot-market opportunities.

The Chemours project is expected to commence by the end of Q2FY27, followed by a gradual 15-month ramp-up. Navin Fluorine’s site is the sole manufacturing site for Chemours. The Honeywell HFO manufacturing agreement runs for seven years, with an option for a further three-year extension.

Speciality Chemicals

Management cited continuing generic crop-protection pricing pressure, particularly in Latin America, but highlighted a shift towards patented molecules and innovator customers. Three of the five planned FY27 campaign molecules are patented.

Multipurpose plant debottlenecking remains due in Q3FY27 and is expected to deliver nearly 2x asset turnover.

Financial Estimates and Valuation

Management expects consolidated EBITDA margin to remain broadly within 30 to 33 per cent, with around 1 per cent variation depending on mix and market conditions. ICICI Securities’ estimates are as follows:

The broker applies a 45x multiple to FY28E EPS to arrive at its Rs 9,635 target price and believes the company’s growth momentum and execution support a premium valuation.

Key Risks

• Competition and pricing pressure in R32.
• Slower-than-expected ramp-up in Advanced Materials.
• Slower-than-expected ramp-up in the CDMO business.